Navigation Links
Merck & Co., Inc. Response to Today's New York Medicaid Suit
Date:9/17/2007

WHITEHOUSE STATION, N.J., Sept. 17 /PRNewswire/ -- Merck & Co., Inc. today said that it has not yet received a complaint reportedly filed by New York State and New York City seeking Medicaid reimbursement costs. The Company intends to defend against the suit as it has defended against the Medicaid- related suits filed more than a year ago by a handful of other states.

Merck carefully studied VIOXX(R) before and after receiving U.S. Food and Drug Administration (FDA) approval, and consistently made the results of those studies available to the FDA and the medical and scientific communities. Merck acted responsibly from researching VIOXX prior to approval in clinical trials -- to monitoring the medicine while it was on the market -- to voluntarily withdrawing the medicine when it did. In fact, the Company acted within a week after one of its own studies suggested, for the first time, an increased relative risk with VIOXX compared to placebo which became apparent after about 18 months of continuous use.

The fact is that VIOXX worked for patients because it was effective at relieving pain with fewer gastrointestinal effects than other medicines in its class. Additionally, heart attacks and the injuries alleged in the suit were common before VIOXX was ever on the market and they remain common today. The medicine was labeled appropriately under the direction of the FDA according to the evolving science available at the time it was on the market.

Before today, Merck was facing six actions filed more than a year ago by the Attorneys General of the states of Alaska, Louisiana, Mississippi, Montana, Texas and Utah. All of the Attorney General suits seek to recover the Medicaid funds the states spent on the medicine. The Alaska, Louisiana, Mississippi, Montana and Utah cases are in the federal multi-district litigation (MDL) proceeding in New Orleans. The Texas proceeding is pending in Texas state court in Austin, Texas.

Status of Litigation

In personal injury trials related to VIOXX, juries have decided in favor of Merck 10 times and in plaintiffs' favor five times. There have been two mistrials and a federal judge recently set aside one of Merck's 10 verdicts.

For information regarding additional cases scheduled for trial in 2007 visit http://www.merck.com/newsroom/vioxx.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit http://www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Media Contact: Kent Jarrell Investor Contact: Graeme Bell

(202) 230-1833 (908) 423-5185


'/>"/>
SOURCE Merck & Co., Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck in the Dock Due To Vioxx
7. Merck Says Januvia Effective In Type 2 Diabetes
8. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
9. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
10. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
11. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology: